Percutaneous drug penetration: Choosing candidates for transdermal development by Flynn, Gordon L. & Stewart, Barbra H.
Drug Development Research 13:169-185 (1988) 
Percutaneous Drug Penetration: Choosing 
Candidates for Transdermal Development 
Gordon L. Flynn and Barbra Stewart 
College of Pharmacy, Pharmaceutics Group, College of Pharmacy, 
The University of Michigan, Ann Arbor 
ABSTRACT 
Flynn, G.L., and B. Stewart: Percutaneous drug penetration: Choosing candidates for 
transdermal drug development. Drug Dev. Res. 13:169-185, 1988. 
There is currently a high level of interest in using the skin as a route for delivering drugs. 
One hears the questions: What are the attributes of a drug that make it a serious 
candidate for transdermal delivery? By what a priori analysis might one zero in on the 
best transdermal candidate within a family of drugs? Answers to these questions lie in 
understanding the molecular factors that make a drug a facile permeant of the skin. 
Among other properties, it must have a high absolute affinity for the skin’s phases, which 
provide for its diffusive conduction. Other factors in evaluation are the potency of the drug 
and the relative efficiency of the drug’s systemic presentation once it has gained access 
to the body. One also considers the potential for the drug to elicit adverse responses in 
the skin. Fortunately, parallels between the drug’s ability to partition between oil and 
water and its ease of mass transfer across the skin can be used to ferret out a working 
mass transfer coefficient. If not already known, solubilities are easily experimentally 
deduced. The extent of first-pass metabolism by the oral route, presumed to be a known 
quantity, is compared with the relative amount of metabolism of the drug in the course of 
its diffusion through the skin, an experimentally determined quantity, in order to set the 
transdermal dose. These bits of information can then be used to form an early, reasonably 
faithful picture of the feasibility of delivering a particular drug transdermally and to make 
a first estimate of the size of patch required for the drug. 
Key wards: skin permeability, transdermal delivery, percutaneous absorption, structure- 
activity relationships, selecting drug candidates 
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INTRODUCTION 
For as long as it has been appreciated that substances exist in nature that alleviate pain 
and suffering, man has sought the means to administer them to gain their full advantage. One 
can presume that the oral route figured prominently in prehistoric medicine, for taking drugs 
orally is as natural as eating. One can also presume that early man encountered some of the 
general difficulties that still exist with the oral route, namely problems attending administra- 
tion of drugs to nauseous and unconscious patients. Alternative methods of administration 
were surely attempted, with the topical route certainly amongst those tried, given its 
accessibility and extensiveness. Drugs were apparently used topically by early Egyptian and 
other Mediterranean civilizations not only to treat surface wounds and the local manifestations 
of disease but also to cure general illnesses. Poultices, cataplasms, and plasters were still in 
wide use as cold remedies and for other human afflictions at the dawn of the 20th century. 
However, only in the last 20 years has it proven possible to unequivocally demonstrate that 
systemic therapy by the topical route, though subject to severe constraints, is indeed feasible. 
We seem to be passing through a period in which the commercial lure of transdermal 
delivery is running out in front of our comprehension of the administration method. Many, 
many hours have therefore been spent in the laboratory and clinic learning the hard way that 
many drugs fail stringent tests of potency and toxicity requisite for their delivery through the 
skin. Wouldn’t it be nice if screening to sort out the most promising drugs for the method could 
be accomplished in the library with the aid of pencil and paper and a keen sense of the 
processes involved? If one can accept an order of magnitude answer, this is, in fact, possible! 
The present report aims to establish this point. It catalogs obstacles to the successful 
deployment of the transdermal method of delivery and especially concentrates on the 
physicochemical and biophysical constraints associated with permeation of the skin. The 
relatively impermeable strata of skin interposed between the surface of the body and the 
systemic circulation are a prime consideration. Although a conservative stance is taken with 
respect to the delivery method, this report actually places transdermal delivery in a positive 
light, for, when the principles set forth are applied, one can rule out unworthy drugs and 
concentrate effort on candidates of high promise. It emphasizes two points: 1) the information 
required for the initial judgement about the transdermal potentials of drugs; and 2) the 
application of the information to make enlightened decisions. While the topical delivery of 
drugs to achieve their systemic effects is of sole concern, the general approach to the selection 
of drug candidates can also be applied to the selection of drugs best suited for local therapy. 
PERCUTANEOUS ABSORPTION 
Transepidermal Absorption 
Percutaneous absorption involves passive diffusion of substances through the skin. The 
mechanism of permeation can involve passage through the epidermis itself or diffusion through 
shunts, particularly those offered by the relatively ubiquitously distributed hair follicles and 
eccrine glands (see Fig. I). While exceptions to the rule are acknowledged, it is now generally 
believed that the transepidermal pathway is principally responsible for diffusion across the 
skin. Far more often than not, the main resistance encountered along this pathway arises in the 
stratum corneum. Characterization of the physical nature of the skin barrier thus should begin 
with characterization of the stratum corneum. 
Over most of the body, the stratum corneum is composed of 15 to 25 layers of “acutely 
flattened, metabolically inactive cells” [Odland, 19831. It is surprisingly dense for a soft 
tissue, having an estimated dry weight density of 1.3-1.4 gm/cm3 [Scheuplein, 1978; 
Scheuplein and Bronaugh, 19831. The thickness of individual cell layers varies, ranging from 
0.2 pm to 0.5 km, depending on location [Plewig et al., 19831, but appears to be uniform at 
a location. The individual platelets, which function as building blocks, appear as crudely 
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TRANSECCRINE I 
Fig. 1 .  Illustration showing the possible routes for percutaneous absorption. Currently it is believed that 
a transepidermal route through the seams between the “cells” of the stratum corneum is the principal 
pathway for most drugs. 
shaped polygons. In their longest dimension these measure 30-40 Fm. By the time the cell 
platelets are laid into the stratum corneum, the cell interior is crisscrossed with densely packed 
bundles of keratin fibers [Steinert, 19831. Due to this, the dry composition of the horny layer 
is 75-85% protein, most of which is intracellular keratin. A fraction of the protein also appears 
to be associated with a still intact network of cell membranes. The bulk of the remainder of the 
substance of the stratum corneum is lipids. Elias and coworkers [ 19831 make a strong case that 
the stratum corneum’s lipoidal substance lies almost exclusively in the seams between cells. 
It appears to be organized into bilayers. The greater part of this lipid originates from membrane 
coating granules found in the granular layer. These pass from the granular cell’s interior into 
the intercellular space as one of the culminating events of differentiation of the epidermal 
keratinocyte. The stratum corneum thus has two distinct chemical regimes, the mass of 
intracellular protein and the intercellular lipoidal medium. These phases are isolated from one 
another by still present, and presumably intact, cell membranes. The cell membranes 
themselves are knit together by desmosomes, adding a tough infrastructure to the horny mass 
[Goldsmith, 19831. This conceived structural organization supports the idea that a lipoidal 
route exists between the cells, possibly with alternative pathways through the mass of protein 
[Scheuplein, 1965, 1967, 1976, 1978; Scheuplein and Bronaugh, 1983; Katz and Poulsen, 
1971; Flynn, 19851. The intercellular lipid route occupies 1% of the stratum corneum’s 
productive diffusional area (area in the plane of the skin and perpendicular to permeation) by 
rough estimate [Flynn, 19851. As meager as it is, this description captures most of what is 
accepted about the organization of the stratum corneum’s physically distinct phases. The 
picture arrived at is to an uncomfortable degree still tentative, making a more refined 
description of the tissue’s potential diffusion pathways hazardous. 
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When a permeating drug exits the stratum corneum, it enters the wet cell mass of the 
epidermis, and, since the epidermis has no direct blood supply, the drug is forced to diffuse 
across it to reach the vasculature immediately beneath. Given that this mass of viable cells 
gives rise to the stratum corneum, it is remarkable how different its barrier properties are. In 
the live epidermis several histologically distinguishable layers of closely packed cells form a 
tight, cellular continuum 50-100 pm in thickness. At its base, the epidermis forms an 
irregular, papillate interface with the dermis. The basal cells are overlaid on a thin basement 
membrane and are anchored to the dermis by tiny fibers. Proliferating stem cells in the basal 
layer give rise to all epidermal cell layers above. The basement cells tend to be cuboidal or 
columnar in shape, but, as they progress toward the horny layer, they undergo profound 
changes in appearance. Sharp, spiny protuberances form at points of cell attachment 
immediately above the basal layer (stratum spinosum). As the cells near the undersurface of 
the stratum corneum, they flatten considerably and stain to give a granular appearance (stratum 
granulosum). The nucleus and cell organelles are still visible in the granular cell’s interior as 
are keratohyalin substance, the preferential staining of which gives the granular appearance, 
and small lipid-filled vesicles known as membrane coating granules. The latter particles pass 
by exocytosis into the space between cells in the final stage of formation of the stratum 
corneum. Though appearing granular and full of vesicles and cell organelles, there is little 
reason to believe that the barrier qualities of the granular layer are unique within the viable 
epidermis. Rather, and as a practical matter, the viable epidermis, mitotic layer to granular 
layer, is considered as a single field of diffusion in models. A considerable amount of 
experimental and other evidence indicates it is a permeable field that functions as a viscid 
watery regime to most permeants [Scheuplein, 1965, 1967, 1976; Flynn, 19851. It appears that 
only ions and polar nonelectrolytes found at the hydrophilic extreme and lipophilic nonelec- 
trolytes at the hydrophobic extreme have any real difficulty passing through the viable field 
[Flynn, 19851. The epidermal cell membranes are tightly joined and there is little to no 
intercellular space for ions and polar nonelectrolyte molecules to diffusionally squeeze 
through Thus permeation must follow a course that requires frequent crossings of cell 
membranes, each crossing being a thermodynamically prohibitive event for such water-soluble 
species. Extremely lipophilic molecules, on the other hand, are thermodynamically con- 
strained from dissolving in the watery regime of the cell (the cell cytoplasm). 
A rich bed of capillaries is encountered 20 pm or so into the dermal field. Passage 
through this dermal region represents a final hurdle to systemic entry. This is so regardless of 
whether permeation is transepidermal or by a shunt route. The dermal construction is a mesh 
of collagen fibers and is the principal structural element of skin. Wide spaces between the 
bundles of collagen fibers are filled with a watery gel called the ground substance. Permeation 
through the dermis is through the interlocking channels of ground substance formed between 
fibers. The gaps between fibers are far too wide to filter large molecules and thus, as far as can 
be told from existing information, diffusion through the dermis is facile and without molecular 
selectivity. Because the viable epidermis and dermis lack major physicochemical distinction, 
they are generally considered as a single field of diffusion [Flynn, 19851. An exception to this 
generalization is made for solutes of extreme polarity, as the epidermis offers a factorable 
resistance to such species. 
Permeation by the transepidermal route first involves partitioning into the stratum 
corneum. Diffusion across this tissue, the viable epidermis, and the upper dermis then ensues. 
The current popular belief is that most substances diffuse across the stratum corneum via a 
lipoidal pathway, which recent histological evidence places between the cells [Elias et al., 
1983). This is a tortuous pathway of limited fractional volume and even more limited 
productive fractional area in the plane of diffusion. The presence and nature of this pathway 
explain the greater part of the existing chemical structure-skin permeation data [Flynn, 19851. 
However, there appears to be another microscopic path through the stratum corneum for 
extremely polar compounds and ions. Otherwise these would not permeate at rates that are 
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measurable, considering their o/w distributioning tendencies [Flynn, 19851. In the other 
extreme of polarity, lipophilic molecules concentrate in and diffuse with relative facility 
through the horny layer’s intercellular regime only to find themselves blocked by the wet cell 
mass beneath. Thus the viable tissue is rate-determining when nonpolar compounds are 
involved [Scheuplein, 1965, 1967, 1976; Flynn, 19851. 
Transfollicular (Shunt Pathway) Absorption 
Arguments have raged about the true pathway for percutaneous absorption, but it is now 
the generally accepted view that the skin’s appendages offer only secondary avenues for the 
permeation of most chemicals. Sincc pilosebaceous and eccrine glands are distributed over the 
entire body, except for some very limited, isolated areas, only these appendages are ever taken 
seriously as shunts bypassing thc stratum corneum. Though eccrine glands are numerous, up 
to 400 glands per cm2 in places such as the palms and soles, their orifices are tiny and add up 
to a miniscule fraction of the body’s surface. Moreover, they are either evacuated or so 
profusely active that it is unlikely that molecules can diffuse inwardly against the gland’s 
output. For these reasons they are discounted as a significant route for percutaneous 
absorption. 
Pilosebaceous glands are less numerous than eccrine glands, having a density variously 
estimated to be between 50 and 100 glands per cm2 of body surface. However, the opening of 
the follicular pore where the hair shaft exits the skin is relatively large; the fractional area of 
the route has been estimated to be as high as I/l,000th of the skin’s surface [Flynn, 19851. 
Moreover, the duct of the gland is filled with a soft, slowly extruded lipoidal medium, sebum, 
in which lipophilic drugs should be soluble and through which they should diffuse with ease. 
Thus the follicular route remains as a possibly important avenue for percutaneous absorption. 
Partitioning into sebum followed by diffusion through the sebum to the depths of the epidermis 
is the envisioned mechanism of permeation by this route. Vasculature subserving the hair 
follicle located in the dermis represents the likely point of systemic entry, 
Clearance by the Local Circulation 
The earliest possible point of entry of drugs and chemicals into the systemic circulation 
is within the papillary plexus in the upper dermis. The process of percutaneous absorption is 
generally regarded as ending at this point, a presumption that is almost certainly a model-based 
oversimplification, as some molecules clearly bypass the circulation and diffuse deeper into 
the dermis. Blood flow through the superficial capillary plexus is highly variable. For one 
thing, the level of perfusion of blood is determined by the existing physiological need to 
conserve or eliminate body heat. Whether the flow of blood through chilled skin is adequate 
for efficient local clearance of pcrmeant is an important question having no current answer. 
Blood flow is also exaggeratedly increased by local trauma. On the other hand, clearance may 
be diminished in old age due to vascular decrepitude. This thought has sparked the suggestion 
that aged skin is more prone to the allergic and irritant effects of topically contacted 
compounds [Kligman, 19791. Despite these collective concerns, the preponderance of 
evidence seems to indicate that local clearance is relatively efficient. 
The above is a thumbnail skctch of the principal features of the skin as they relate to the 
inward diffusion of chemicals from the skin’s surface. It is clear that the development of 
models for skin permeation must include diffusion across a series of barriers and possibly 
diffusion through parallel pathways. Moreover, certain anatomical structures of the skin are 
relatively impervious, a factor that limits the available area for diffusion and forces permeation 
mainly through the limited fraction of soft lipoidal material between the stratum corneum cells 
or through sebum in the follicular duct. Clearance is by way of the blood, the flow of which 
varies depending on momentary physiological need. 
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SKIN PERMEATION ASSESSMENT 
Diffusion From a Saturated Medium in Contact With the Skin 
In order to make an assessment of the systemic availability of a topically applied drug 
(or topically contacted chemical), one normally has to consider the separate but concerted 
delivery processes of drug release from the topical vehicle (or medium containing the 
chemical) into the skin and diffusion through the skin. However, to assess whether a drug can 
be delivered transdermally for systemic therapy, it is only necessary to consider the latter 
process. This is so because it is presumed ah initio that the means will be found to maximize 
(or optimize) a drug’s thermodynamic potential at the skin’s surface, providing the drug’s 
percutaneous absorption rate is consistent with therapeutic needs. Removing all considerations 
of vehicle control to make the first assessment of feasibility of delivery considerably simplifies 
the analysis. What one in effect does is estimate the maximum rate at which the drug can be 
caused to diffuse across the skin. It’s easy to back off from this rate should it be overly fast. 
The maximum rate will be achieved at the attainable limit of thermodynamic activity of the 
drug. For a crystalline drug (most drugs of interest are going to be in the form of molecular 
crystals), the maximum attainable thermodynamic activity is set by the neat solid. Therefore, 
for the purpose of establishing feasibility, transdermal drug delivery from a continuously 
saturated solution through the skin is assumed. While the dominant resistance of the skin 
usually lies in its stratum corneum, the outermost, 10-Fm-thick, devitalized layer of the tissue, 
there are times and circumstances when other strata of the skin in series with the stratum 
corneum offer appreciable resistances to diffusion or when shunt routes are followed and 
cognizance is taken of this in the general analysis. 
Situations in which a drug is delivered from a reservoir in which it is at unit activity 
(from a saturated solution) through a resistant membrane like the stratum corneum (or whole 
skin) are frequently encountered in transdermal delivery. Equation 1 mathematically describes 
the delivery dependency: 
Here M, is the amount of a drug passing through a unit area of the membrane in time, t, under 
conditions that the drug is delivered from a saturated reservoir of concentration, C,. K is the 
skidvehicle partition coefficient, making the product, K C , ,  the saturation concentration of the 
drug within the skin’s surface. The terms within the summation, D,, and h,,, are the efsective 
diffusion coefficient and the effective thickness of the stratum corneum or, more generally, the 
membrane, respectively. Though subscripted with sc to designate the stratum corneum, they 
are in fact functional parameters representing the net properties of all consequential strata. 
Even when the stratum corneum is the sole source of diffusional resistance, D,, and h,, are 
eflective parameters because there is no way to make an explicit accounting for important 
factors such as the fractional area and tortuosity of the route taken through the stratum 
corneum. 
The theoretical curve (schematically drawn) depicted in Figure 2 is based on equation 1. 
The curve indicates that no drug or very little drug penetrates the skin in the early moments 
after the application of the drug-containing reservoir. However, once the first molecules 
breach the membrane, the flux of the drug gradually grows until it reaches a steady level. One 
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Fig. 2. Schematic representation of the standard permeation profile (amount penecrated through the 
membrane as a function of time), which is obtained using a two-compartment diffusion cell. The intercept 
of the steady-state line (equation 2 in the text) is the lag time (equation 4 in the text). 
K . D,, . C, [ t - -  h s2 )  
M, = 
hsc 6D,, 
In effect, equation 2 describes a situation in which the amount penetrating per unit time is 
constant, the steady-state condition. The steady-state flux, dM,/dt, is readily obtained from 
equation 2 by differentiating M, with respect to t ,  i.e.: 
dM, = K . D,, . C, -
dt h,, 
(3) 
When the steady-state line is extrapolated to the time axis, the value o f t  at M = 0 is found 
to be: 
This intercept, tL, is refcrred to as the lag time. In essence, it is a measure of the time it takes 
for the permeant’s concentration gradient to become stabilized across the membrane. In 
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principle (with the simplest of membranes), the diffusivity can be calculated from tL providing 
the membrane thickness is known. With a complex membrane such as the skin, only an 
eflective value of the diffusivity is obtained. 
The essential meanings of equations 1 through 4 can be considered. Equation 4 tells us 
that the lag time for penetration becomes longer as the effective diffusivity, D,,, becomes 
smaller (irrespective of how it is calculated). Normally one wants the lag time to be a 
negligible fraction of the projected time of use of a transdermal system. If the prescribed period 
of application is to be a day, as it is with current nitroglycerine patches, the lag time should 
be no more than a tenth of a day or 2-3 hours at the most. Any lag time longer than this raises 
questions about the utility of the patch, for the patch will not be delivering drug over a 
significant part of the time it is in use. Consequently, the attainment and maintenance of even 
blood levels will be next to impossible. In vitro diffusion cell studies suggest that the values 
of D,, for the stratum corneum (one uses the stratum corneum’s 10-km thickness in the 
calculation) range from lop9 down to cm2/sec [Scheuplein, 1978; Scheuplein and 
Bronaugh, 19831. At the larger diffusivities, lag times of several minutes are expected. On the 
other hand, multiple-day lag times are suggested by the smallest reported diffusivities. In our 
actual experience, diffusional lag times range from several hours to over half a day for 
nonelectrolyte drugs having molecular weights of 200 daltons or more. Moreover, the more 
polyfunctional and polar a compound is, the longer its lag time seems to be. For example, lag 
times across cadaver skin membranes for the permeation of fentanyl and sufentanil, both 
narcotics of low polarity based on partitioning data, have consistently been less than 3 hours. 
In contrast, lag times for morphine and hydromorphone, both relatively polar narcotics, have 
consistently exceeded 6 hours, well over than twice those of fentanyl and sufentanil. This 
alone poses a problem with respect to their transdermal delivery. Clearly, thefirst obstacle to 
transdermal delivery is overly long lag times. Fortunately, in vitro diffusion cell methods 
appear to be able to indicate when this is going to be a problem. 
Equation 1 indicates that, providing enough time is allowed to elapse, a steady state in 
permeation is obtained. The rate of delivery in the steady state is described by equation 3. The 
steady state arises in part because delivery is from a reservoir of constant thermodynamic 
activity. The development of a steady state also requires the barrier properties of the skin 
membrane to be invariant over the lifetime of patch use (or over the duration of a diffusion cell 
experiment). For the purpose of analysis, we will assume the skin membrane is stable, in 
which instance equation 3 tells us that the per unit area rate of delivery is proportional to the 
product of the saturation concentration, C,, diffusivity, D,, and the partition coefficient, K ,  
as well as inversely proportional to the thickness of the membrane, hsc. The product, K . C,, 
yields the saturation concentration in the surfacemost structure of the stratum corneuml and is, 
at least theoretically, independent of the nature of the medium used in the reservoir. The 
process is driven by the activity of the solid state; the gradient across the skin directly reflects 
this activity. For a complex membrane such as the skin, derived values for D,,, K,  and h,, have 
magnitudes that depend on assumptions about the nature of the membrane. Since they cannot 




-= P + C, = constant 
‘A mechanism of permeation of a drug involving diffusion of the drug across the stratum corneum, the 
so-called transepidermal pathway, is assumed. However, the principles set forth arc general with the 
assumption having no practical consequence on the analysis. 
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where P is the mass transfer coefficient or “permeability coefficient. ” The total flux in the 
steady state is therefore: 
where now the area, A, is explicitly considered. It is obvious that, in any designated small 
increment of time, the total amount of drug that permeates the membrane, dMt,Totd, is equal 
to the volume of the collecting phase, V, times the change in concentration of this phase, dC,. 
It is these forms of equation 3 that are used to calculate permeability coefficients from data 
gathered in in vitro studies. This is possible because the area available for diffusion in the 
diffusion cell and the solubility or, more generally, concentration of the drug in the medium 
applied to the skin mounted in the diffusion cell are independently measured and known prior 
to starting an experiment. The in vitro experiment is begun, and the flux in the steady state is 
measured. From these, one calculates the proportionality constant between flux and the 
product of area and concentration. This is what the permeability coefficient actually is. It takes 
a value that is uniquely dependent on: 1)  the chemical structure of the drug; 2) the 
physicochemical nature of the medium of application; and, of course, 3) the physicochemical 
nature of the membrane. 
When the membrane and medium of application are fixed, differences in permeability 
coefficients through a family of drugs are strictly related to the differences in chemical 
structures of the drugs. Clearly, the larger the value of P, the greater the flux of the compound, 
all other factors being equal. According to Flynn 119851, permeability coefficients for hairless 
mouse skin determined from saline (or isotonic aqueous buffer) range from about to 
about cmhour, with indications that they take levels ten times smaller in human 
epidermis on the lower side of the range. Using 1 mgiml as a reference concentration2 and the 
maximum permeability coefficient of lo-* cmihour, one calculates that 20 pg of drug passes 
through the skin membrane pcr hour per cm2. This amounts to about 0.5 mglcm2iday. By 
chance, this is almost exactly the amount of nitroglycerine that can be induced to diffuse 
through the skin. Nitroglycerine is a liquid at room temperature. It also has the requisite 
physicochemical properties to place it at the high end of the permeability scale. Since it has 
these ideal properties for transdermal delivery, it would appear that a flux of one half mg per 
day per cm2 should be near the upper limit of attainable flux. At the lower end of the 
permeability coefficient scale, the computed daily delivery is, for all practical purposes, 
negligible unless permeation is from very high concentrations of a drug.3 Thus, u smull 
permeability coeficient sets the second physical limitation on trunsdermal delivery. 
Equation 5 indicates that a second general factor determining flux is the concentration 
of the drug in the medium of application. As pointed out, the limiting mass transfer rate is seen 
when permeation is from a saturated solution. In general, supersaturation leads to a metastable 
situation and cannot be relied upon. In order to use equation 5 ,  one must know the solubility 
of the drug in the medium that was used in the assessment of the permeability coefficient. 
Almost invariably the solubility of interest will be the solubility in water, as the vast majority 
of published permeability coefficients for the skin have been determined using aqueous media. 
’Note that only relatively hydrophobic drugs have permeability coefficients as large as 1 x lo-’ 
cdhour, and these rarely have solubilities in water as high as 1 mgiml. 
3However, large, polyfunctional, polar compounds tend to be highly crystalline and, consequently, none 
too soluble in any phase. 
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Consequently, any scheme for estimating permeability coefficients will of necessity be 
referenced to data generated in watery media. 
Several completely separate factors have a bearing on solubility, including the ease of 
dissociation of a molecule from its crystal and the degree of interaction of dissolved solute 
molecules with the solvent. High-melting, hard crystalline materials with large enthalpies of 
fusion are predictably less soluble than soft, low-melting crystals, everything else being equal. 
It turns out that hydrophobic molecules have low intracrystalline cohesiveness and, according 
to this factor, tend to be relatively soluble. However, the net negative free energy of solution 
of hydrophobic molecules in water is small, meaning such molecules have low aqueous 
solubilities. On the other hand, hydrophobic crystalline organics tend to be highly soluble in 
nonpolar media, including the conduit phases of the skin. As a consequence, they have large 
permeability coefficients, which tend to more than compensate for their low water 
Molecules containing multiple hydrogen bonding centers andlor strong dipoles are 
generally high-melting because of strong intracrystalline self-association. While such mole- 
cules react strongly with water, imparting a degree of solubility in this solvent, they do not 
dissolve substantially in organic phases, because of the exaggerated cohesive energy difference 
between polar solute and nonpolar solvent. Consequently, partitioning into the lipoidal conduit 
phases of the skin is minimal, and mass transfer rates are low even from their saturated 
solutions. It is clear then that low solubility is the third physical obstacle to transdermal 
delivery. 
Transdermal Delivery Rate Projection 
The above discussion indicates that the transdermal delivery rate of a drug can be 
forecast providing one knows the drug’s solubility in and permeability coefficient from a given 
solvent medium. It further suggests that the logical solvent medium on which to base such 
projections is water. One can often find the aqueous solubilities of drugs in compendia or the 
research literature. When the solubility of a compound of interest is not available, it is a 
reasonably straightforward task to determine it, generally a 1-day experiment, providing there 
is an ample supply of drug. In doing so, one has to account for the ionization of weak 
electrolytes, so that the correct solubility of the drug can be assigned to the solid state 
representing the nonelectrolyte form, for it will be the partition coefficient of the free form that 
will be used to estimate a permeability coefficient. In principle, one also should be able to 
es by one of several empirical methods. However, it has been our experience 
that solubilities determined by the best of such methods, for instance, those based on the 
melting points of drugs and their octanol/water partition coefficients [Yalkowsky, 19811, are 
not sufficiently reliable for predictive purposes. 
Permeability coefficients are neither prevalent in the literature nor so easily determined; 
there is no immediately obvious means of estimating them that does not involve permeation 
experiments. However, on careful examination of the literature, one finds prediction-useful 
relationships between the permeability coefficients of drugs and their partitioning tendencies. 
Flynn [ 1985) has discussed how the permeability coefficients of test compounds through 
hairless mouse skin relate to the ethedwater partition coefficients of the compounds. The 
reported data are displayed in Figure 3. It can be seen that compounds having molecular 
weights greater than 200 daltons all seem to lie on a sigmoidal line stretching over ten 
logarithmic orders of partition coefficient. The upper limit on the values is slightly above lo-* 
e ~ . ~  For this reason, high fluxes are seen with moderately hydrophobic drugs. 
40ne can view this another way. Although the solubility of a hydrophobic compound in water is low, the 
product of this solubility and the partition coefficient into the skin is likely to be large, meaning that the 
drug’s solubility in the surface structure of the skin is large. This goes hand in hand with the presumed 
permeability coefficient. 
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Fig. 3. Plot showing how the permeability coefficients of a number of test compounds and drugs 
through hairless mouse skin relate to their etheriwater partition coefficients. For compounds of molecular 
weight > 200 daltons, all data fall on or reasonably close to a sigmoidal line spanning about ten log orders 
of magnitude of partition coefficients (X-axis) and over three log orders of permeability coefficients 
(Y-axis). 
cdhour  and is attained at etheriwater partition coefficients greater than 500 (log,, = 2.7). 
Over the range of partition coefficients from 0.01 (loglo = -2) to 100 (log,, = +2),  the 
permeability coefficients increase by three logarithmic orders. Finally, compounds with log 
(permeability coefficients) less than - 2 all fall on a line just above P = cmihour. We 
have found that these permeability coefficients fit to a similar general pattern on an 
octanoVwater partition coefficient scale. 
Permeability Analysis-Top 200 Drugs 
To put the principles outlined above to a stringent test, it was decided to apply them to 
an evaluation of the transdermal delivery potentials of the drugs in the top 200 new prescription 
drug products of 1985’. The top 200 list is actually one of products, not chemical entities, and 
is full of entity redundancy. Moreover, it was found that the necessary information to make 
projections was available for only 22 (= 15%) of the actual chemical entities on the list. 
Twenty-two compounds are nevertheless a sufficient cache of drugs to give fair assessment of 
the utility of any estimative approach. 
Establishing the daily transdermal drug requirement was the first step taken toward 
estimating the transdermal potentials of the indicated drugs. It was reasoned that this would be 
equal to the total 24-hour oral dose adjusted downward for oral first-pass loss. Oral dosages 
were drawn from standard compendia [Huff, 1986; Boyd, 19811. First-pass information was 
mainly found in Goodman and Gilman’s classic pharmacology text [Goodman et al., 19851. 
No data on oral first-pass extraction could be found for 8 of the 22 compounds listed in Table 
I .  No attempt was made to account for conceivable but relatively improbable metabolism in 
the skin (see the final paragraphs of this essay). The formula for computing the dose was: 
5A manuscript by B.  H. Stewart, G .  L. Mynn, N. Sheth, and S.  D. Roy entitled Physiochemical 
assessment of the transdermal delivery potentials of drugs is in preparation. 
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TABLE 1. Selected Drugs From the Top 200 (1985 List) Used to Test the Method of Assessing 
Transdermal Delivery Potentials 
Total daily Estimated 24-hr 
Permeability Aqueous transepidermal transepidermal Patch 
coefficient' solubilityb dose"." deliverye size 
Chemical name ( c d h r  X lo3) (mgiml) ( m d  (mg/cm2) (cm2) 
Acetylsalicylic acid 3.25 3.3 1,ooo 0.0257 - 
Chlorpropamide 0.036 2.2 225 0.0019 - 
Codeine phosphate 0.41 8.3 120 0.082 
Allopurinol 0.016 0.48 250 0.00018 - 
Amoxicillin 1.48 4.0 700 0.142 - 
Clonidine 3.82 30.0 0.2 2.75 <1 
Dexamethasone 19.6 0.1 4 0.047 85 
Erythromycin 20.0 2.0 350 0.960 - 
Erythromycin estolate 20.0 0.024 350 0.0115 - 
Estrone sulfate 20.0 0.03 - 1.25 0.0144 87 
Haloperidol 20.0 0.014 2.0 0.0067 - 
Hydorcortisone acetate 5.27 0.01 200 0.0013 - 
Lorazepam 20.0 0.08 4 0.0384 104 
Methyldopa 0.2 10 150 0.048 - 
Nicotine 2.96 100.0 - 20 7.1 2.8 
Nitroglycerine 20.0 1.25 2.5 0.6 4.2 
Penicillin V 20.0 0.25 750 0.12 - 
Piroxicam 6.21 0.01 20 0.0015 - 
Phenytoin 20.0 0.013 300 0.0062 - 
Tetracycline 0.014 1.70 1,000 0.00057 - 
Theophylline 0.19 8.3 385 0.038 - 





"Permeability coefficients were estimated from the octanouwater partition coefficient using the formula 
found in the text. 
bAll values for the solubilities were obtained from the literature and were rounded to a comfortable 
magnitude. 
"The daily transdermal dose is equal to the daily oral dose X (100 - % extracted via first pass). 
"No data on first-pass extraction could be found for the compounds with underlined values. 
"See equation 8 in the text. 
(7) - D2, h, vansdcmal - D24 hr, oral x (100 - % extracted first-pass) 
Each computed daily transdermal dose, D,, hr, transdemal, was rounded to the nearest whole 
number; the doses are given in column 4 of Table I .  
The literature was then scoured for the aqueous solubilities of the listed compounds. The 
Merck Index [Windholz, 19831 was relied on heavily for these. The paucity of solubility 
information on the compounds in the top 200 list limited the number of projections that could 
be made. Very few reliable, experimental, aqueous solubilities were found. Solubilities 
obtained from the literature are provided, in units of mg/ml, in columns of Table 1. 
With the exceptions of nitroglycerine and clonidine, little if any skin permeation data 
appear in the literature for the 22 test compounds. Thus all but two permeability coefficients 
had to be estimated. Moreover, given the purpose of the exercise, the permeability coefficients 
of nitroglycerine and clonidine were estimated exactly like the others so they might serve to 
check the method. Permeability coefficients were also estimated for estradiol, fentanyl, and 
scopolamine so that projected delivery rates could be compared with experimental data (Table 
2). Therefore a means had to be devised to assign permeability coefficients to the drugs. It has 
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TABLE 2. Transdermal Delivery Calculations on Estradiol, Fentanyl, and Scopolamine 
Chemical CS P, actual P, estimated" M24. aCNd M24, estimatedb 
name (mg/ml) (cdhr)  X lo3 (cm/hr) X lo3 (mg/cm2/day) (mg/cm2/day) 
Estradiol" 0.003 5.2 20.0 0.0004 0.0014 (3.6) 
Fentanyl' 0.20 10.0 20.0 0.0048 0.0096 (2) 
Scopolamine" 75.0 0.05 3 . 9  0.09 6.3 (70) 
"Estimated by the algorithm based on Koctanol,wa,er partition coefficients outlined in the text of the article. 
The partition coefficients were found in Hdnsch and Leo [19791. 
'Experimental data are from Michaels et al. [1975]. Yet to be published data on the permeability 
coefficient and solubility of fentanyl from these laboratories are in very close agreement with the Michaels 
et al. values. 
dThe reported loglo (partition coefficient) of 1.26 on which this permeability coefficient value is based is 
footnoted as "approximate." The value appears inconsistent with the high aqueous solubility of the 
compound and its reported solubilities in apolar organic solvents such as benzene and pet ether. The 
mineral loglo (oil/water) partition coefficient ib - 1.59 [Michaels et al., 19751; the loglo (heptane/water) 
partition coefficient is -2.26 [Hansch and Leo, 19791. 
parentheses: projected 24-hr delivery/experirnentally determined 24-hr delivery. 
been previously mentioned and is well established that permeability coefficients correlate well 
with in vitro partition coefficients [Scheuplein, 1965; 1967; 1983; Michaels et al. ,  1975; 
Elynn, 1985). Because of the existing extensive compilations of octanoliwater partition 
coefficients [Hansch and Leo, 19791, the decision was made to scale the permeability 
coefficients of the compounds to their Koctanovwater partition coefficients. Based on a 
roughed-out plot of the permeability coefficients of certain compounds against their octanol/ 
water partition coefficients, the following algorithm was developed to estimate permeability 
coefficients. For compounds with loglo (Koctanovwater) < -2.301, a lower limit of I x 
cmihour was assigned to the permeability coefficient. In this region the compounds were 
considered polar enough to preferentially pass through the aqueous regime of the stratum 
corneum LFlynn, 19851. For compounds with log 10 (Koctanol,water) values lying between 
- 2.301 and + 2.000, the permeability coefficients were determined from the empirically 
derived relationship: 
It is important that the steepness of this line and the nature of its placement on the octanoliwater 
axis, which, as stated above, involved fitting the line through several experimental data points, 
leaves considerable doubt about the accuracy, and therefore the usefulness, of permeability 
coefficients estimated over this span of partition coefficients. For compounds with log,, 
(Koctmovwater) values > 2.000, an upper limit permeability coefficient of 1 x lop2 cmihour 
was assigned. Compounds fitting into this partitioning range were considered sufficiently 
nonpolar for their permeation rates to be controlled within aqueous strata of the epidermis and 
dermis [Flynn, 19851. 
In some instances, multiple values for the octanol/water partition coefficients of 
compounds on the top 200 list have been reported; when there was a lack of agreement 
between the values, the value that intuitively appeared to be the most reasonable was arbitrarily 
chosen. Permeability coefficients were then computed (units of cmihour) and rounded to a 
comfortable number; they are given in column 2 of Table 1 .  
Using the solubilities and permeability coefficients, the cumulative amount of drug that 
can be made to pass through a 1-cm2 area of skin from a saturated solution in a day, M24hr , 
in milligrams was calculated from: 
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This equation will be recognized as an integrated form of equation 5. Column 5 of Table 1 
gives the estimated 24-hour amounts. Only when within = 100-fold of the total daily 
transdermal requirement (ratio of daily dose to M24hr --- 100) were patch sizes that would be 
adequate to deliver the daily dose computed (last column in Table 1). 
It can be seen from Table 1 that the method of estimation suggests that it is physically 
possible to deliver clonidine and nitroglycerine by the transdermal method and, moreover, that 
clonidine can be offered as a tiny transdermal device. Considering that transdermal products 
are available for both drugs and that clonidine’s patch is indeed small (= 2.5 cm’), all three 
of these projections have been borne out. Nicotine is also projected to be a good transdermal 
candidate. Developments in several laboratories have demonstrated this to be true. However, 
and more quantitatively, the projected daily deliveries of all three of these drugs appear 
overestimated by three- to five-fold. 
The analysis further suggests that dexamethasone, estrone sulfate, lorazepm, and 
possibly haloperidol (ratio = 300) may be borderline candidates for the transdermal method. 
Dexamethasone is not a transdermal candidate for systemic purposes, as it is a corticosteroid 
well suited to oral administration. However, the drug is topically active. At this writing, there 
are strong indications that estrone sulfate is being readied for transdermal use. Lorazepam also 
seems to have genuine transdermal possibilities, but the same can be said for other highly 
potent benzodiazepines. Whether haloperidol is a true candidate has to be researched, but the 
possibility cannot be discounted. No other drug in the list is even close to meeting the minimal 
specifications for transdermal delivery. Some fail because of high daily doses, while others fall 
short because of intrinsically low skin permeabilities. 
The predictive approach can be further challenged by comparing other drugs with the top 
200 list. Predicting the fluxes of drugs currently available or being developed for transdermal 
administration provides an interesting test. Therefore, Koctanovwate,-detenined permeability 
coefficients were estimated for estradiol, fentanyl, and scopolamine [Michaels et al., 197516 
These are found in Table 2 alongside the known values. The estimated permeability 
coefficients for both estradiol and fentanyl are within factors of four of their reported values, 
certainly an acceptable level of agreement, and consequently the Mz4 values, actual and 
projected, are equally close because the same solubility was used for the M24, and 
MZ4, calculations. The predictive method seems to break down with scopolamine, 
however. The estimated permeability coefficient is 70 times the experimental one; conse- 
quently, the estimated daily flux is also 70 times too large. While the octanol/water partition 
coefficient for scopolamine is suspect (see footnotes to Table 2), we suspect the real problem 
with the prediction for scopolamine results from a discrepancy in the relationship between 
octanol/water partitioning and skin partitioning. In other words, the fundamental platform 
upon which the predictive method is based seems itself to be weakening. The permeability is 
overstated by over an order of magnitude. Since the error of estimation overstates rather th‘an 
understates the potential of scopolamine, the compound would not be rejected out of hand as 
a transdermal candidate, however. We suspect further breakdowns as this might occur with 
highly water-soluble compounds that are also highly soluble in oils of intermediate polarity, 
for it is for just such compounds that the correlation between octanoliwater partitioning and 
skidwater partitioning is likely to languish. 
We are currently compiling a broader data base to tighten the estimative method and 
reveal where the method might fall short of expectation. The tendency to overestimate delivery 
at the upper range of partition coefficient suggests that the upper limit value should be cut, 
6Also including date for fentanyl from unpublished research done in these labs 
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possibly by a much as four-fold (to 5 X cmihour). As more data are gathered, the best 
placement for the line at intermediate polarity will become more evident. It almost doesn’t 
matter where the lower limit line is set, as only in the rarest of circumstances will a drug in 
the high polarity regime make the grade transdermally. 
Frankly, we are encouraged by two aspects of the above analysis, first, that the 
transdermal delivery potentials of so many compounds can be identified simply from physical 
parameters that are typically gathered during preformulation exercises, and second, that no 
good candidates “fell through the cracks. ” Presently, the limiting factors in making 
predictions are the lack of availability of aqueous solubilities of the drugs and the disparities 
in reported partition coefficients. Although we have placed the assessment of transdermal 
delivery potential in a tighter quantitative framework than ever before, in reality we offer 
nothing totally new concerning the factors that make transdermal delivery a possibility [Shaw 
and Chandrasekaran, 1978; Chien, 1982; Cleary, 1983; Karim, 1983; Wester, 1985; Guy and 
Hadgraft, 1985; Good, 1986; Walters, 19861. It takes potent drugs! Consider that the identified 
transdermal candidate with the highest dose of those considered, nicotine, only requires an 
estimated 20 mg to be delivered over the course of a day; this is high, as many, if not most, 
candidates for the method of delivery, proven or suspected, have daily doses that are measured 
in whole micrograms, not milligrams. Note also that all the promising candidates had 
permeability coefficients at or near the established limiting value, meaning that all are 
lipophilic. The idea that lipophilic drugs are the most likely drugs to “make it” isn’t fresh. But 
why this dependency on lipophilicity? Here we point out that the most productive routes 
through (or around) the principal barrier layer of skin, the stratum corneum, are lipoidal, which 
favors solution of such species. This fact alone ties the opening discussion to the predictive 
method. Moreover, lipoidal compounds exhibit low molecular cohesiveness, including 
intracrystalline cohesiveness. Therefore they melt at lower temperatures and consume less total 
energy in melting per mole than do polar organics. This makes them generally more soluble, 
although obviously not so in water. This adds to the suitability of lipophilic drugs for 
transdermal delivery, as they are not only more relatively soluble but also more absolutely 
soluble in the skin’s critical diffusion conducting phases. The absolute solubility issue and its 
relationship to low molecular cohesiveness ties in other parameters, like the melting points of 
drugs, that have been used in a priori estimations of transdermal delivery potentials. 
BIOLOGICAL CONSIDERATIONS IN TRANSDERMAL DELIVERY 
lrritancy and Allergy Issues 
Even when a drug has the requisite potency and permeability for transdermal delivery, 
one is not sure the drug will make it to the marketplace in transdermal form because toxic 
reactions within the skin resulting from application of the transdermal delivery system can still 
scuttle the development project. Local imtancy associated with the drug andlor its delivery 
system is a prime concern. The potential of any drug to induce an allergic response in the skin 
is also worrisome. Both factors have caused a good deal of grief and disappointment along the 
transdermal development path, often at the 1 1 th hour when the highest price is paid for setback 
and failure. Part of the problem is that human irritant responses, allergic sensitivities, and 
photosensitivities are not actually predictable. Standard toxicity tests in animals are done in the 
course of development of a transdermal device of course, but, unfortunately, such tests have 
a poor record of extrapolation to the human condition. When no problems are encountered in 
the animal models, the project team may proceed with a drug’s development falsely confident 
and without further questioning. That the drug in question may already be in use by the oral 
route without a significant incidence of skin toxicity only adds to the false sense of security. 
It then comes as a shock when the exhaustively physically tested and fully developed drug 
delivery system is not well tolerated in the clinic. Clearly, irritancy and allergy set a most 
stringent constraint on transdermal delivery. Because of the stakes involved, it behooves the 
184 FlynnandStewart 
development team to obtain an early, direct reading of the human skin toxicity of a drug. This 
requires strategic arranging of the sequencing of development events to bring human skin 
tolerance testing into the foreground. 
It should be pointed out that there is a straightforward reason why drugs that have clean 
dermatotoxicity records when used orally and parenterally can run into toxicity problems when 
topically deployed. Transdermal delivery leads to drug accumulations in the skin directly 
beneath a patch that are many times higher than are ever achieved in the skin through systemic 
administration of that drug. Imtancy (particularly) and allergic responses are known to be 
concentration-dependent phenomena; topical administration has the potential of raising the 
tissue concentrations of a drug (or other component of the transdermal system) above the 
threshold for response. While it appears possible to modulate irritant responses, for instance 
by designing a larger patch that delivers less drug per unit area, it seems that once the skin of 
a patient is sensitized to a drug, that particular drug is forever contraindicated by the topical 
route for that patient. 
Metabolism During Transit Through the Skin 
Another biological factor that can affect transdermal delivery is metabolism of the drug 
in the skin coincident with its diffusive passage across the skin. It is conceivable that little 
intact drug might reach the systemic circulation. Thus local first-pass metabolism at least has 
the potential to act as another constraint on transdermal delivery. However, all current 
experience suggests that this is not a general problem. For one thing, the skin has far less 
capacity to metabolize drugs than have either the liver or the gastrointestinal mucosa, the latter 
of which routinely synthesizes glucuronides and other adducts as drugs are absorbed. 
Moreover, it appears from early observations in these labs that human skin has less capacity 
to enzymatically alter drugs than do the skins of the rat and mouse. In particular, human skin 
seems to have a low esterase activity. Other enzyme activities of the skin, human or otherwise, 
seem to be substrate-specific and purposeful, and unlikely to cause problems with an 
exogenous compound, 
Enzymatic inactivation of a transdermally administered drug in the skin need not be 
dismissed out of hand because of its improbability, for one can easily experimentally establish 
whether or not concern should exist over the issue. The presence or absence of metabolites can 
be demonstrated in in vitro diffusion cell experiments. Such studies also suggest the extent of 
metabolism that will occur as the drug is absorbed. Also, the drug can be incubated with skin 
homogenates to check for metabolism in the presence of all relevant enzyme cofactors. If 
metabolism is possible at all, it will normally show up in such experiments. 
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